PubRank

Strategic Timing of Antiretroviral Treatment (START)

Clinical Trial ID NCT00867048

PubWeight™ 51.73‹?›

🔗 Visit the ClinicalTrials.gov page for NCT00867048

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. N Engl J Med 2015 15.06
2 Timing of HAART initiation and clinical outcomes in human immunodeficiency virus type 1 seroconverters. Arch Intern Med 2011 2.99
3 Considerations in the rationale, design and methods of the Strategic Timing of AntiRetroviral Treatment (START) study. Clin Trials 2012 2.71
4 Universal testing and treatment as an HIV prevention strategy: research questions and methods. Curr HIV Res 2011 2.60
5 Ultrasonographic measures of cardiovascular disease risk in antiretroviral treatment-naive individuals with HIV infection. AIDS 2013 1.23
6 Assessment of arterial elasticity among HIV-positive participants with high CD4 cell counts: a substudy of the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial. HIV Med 2015 1.17
7 Increased HIV testing and reduced undiagnosed infection among gay men in Scotland, 2005-8: support for the opt-out testing policy? Sex Transm Infect 2011 1.14
8 Challenges, successes and patterns of enrolment in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial. HIV Med 2015 1.11
9 Baseline cardiovascular risk in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial. HIV Med 2015 1.11
10 Lessons learned: Infrastructure development and financial management for large, publicly funded, international trials. Clin Trials 2016 1.06
11 Serious Non-AIDS events: Immunopathogenesis and interventional strategies. AIDS Res Ther 2013 1.01
12 HIV and aging: emerging research issues. Curr Opin HIV AIDS 2014 0.91
13 Prevalence of and risk factors for low bone mineral density in untreated HIV infection: a substudy of the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial. HIV Med 2015 0.91
14 Global HIV-1 transmitted drug resistance in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial. HIV Med 2015 0.90
15 Clinical uncertainties, health service challenges, and ethical complexities of HIV "test-and-treat": a systematic review. Am J Public Health 2013 0.90
16 Pulmonary function in an international sample of HIV-positive, treatment-naïve adults with CD4 counts > 500 cells/μL: a substudy of the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial. HIV Med 2015 0.89
17 The evolution of three decades of antiretroviral therapy: challenges, triumphs and the promise of the future. Br J Clin Pharmacol 2015 0.88
18 Baseline prevalence and predictors of liver fibrosis among HIV-positive individuals: a substudy of the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial. HIV Med 2015 0.87
19 CD4 cell responses to combination antiretroviral therapy in patients starting therapy at high CD4 cell counts. J Acquir Immune Defic Syndr 2011 0.87
20 Why START? Reflections that led to the conduct of this large long-term strategic HIV trial. HIV Med 2015 0.86
21 Factors associated with neurocognitive test performance at baseline: a substudy of the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial. HIV Med 2015 0.85
22 Evolution of HIV treatment guidelines in high- and low-income countries: converging recommendations. Antiviral Res 2013 0.85
23 Community perspective on the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial. HIV Med 2015 0.85
24 A scoping study to identify opportunities to advance the ethical implementation and scale-up of HIV treatment as prevention: priorities for empirical research. BMC Med Ethics 2014 0.83
25 The erythrocyte sedimentation rate in HIV: a neglected parameter? AIDS 2010 0.82
26 Reported consent processes and demographics: a substudy of the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial. HIV Med 2015 0.82
27 Cardiovascular disease in HIV patients: from bench to bedside and backwards. Open Heart 2015 0.81
28 Quality of life assessment among HIV-positive persons entering the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial. HIV Med 2015 0.79
29 Will expanded ART use reduce the burden of HIV-associated chronic lung disease? Curr Opin HIV AIDS 2014 0.79
30 Acute coronary syndrome in HIV patients: from pathophysiology to clinical practice. Cardiovasc Diagn Ther 2012 0.79
31 Transmission risk behaviour at enrolment in participants in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial. HIV Med 2015 0.77
32 Demographic and HIV-specific characteristics of participants enrolled in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial. HIV Med 2015 0.77
33 Kidney disease in antiretroviral-naïve HIV-positive adults with high CD4 counts: prevalence and predictors of kidney disease at enrolment in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial. HIV Med 2015 0.77
34 HIV antiretroviral therapy reduces circulating surfactant protein-D levels. HIV Med 2011 0.76
35 Recent key advances in human immunodeficiency virus medicine and implications for China. AIDS Res Ther 2010 0.76
36 Limiting Cumulative HIV Viremia Copy-Years by Early Treatment Reduces Risk of AIDS and Death. J Acquir Immune Defic Syndr 2016 0.75
37 Clinical implications of new findings in HIV basic research. HIV Ther 2009 0.75
38 Clinical and demographic factors associated with low viral load in early untreated HIV infection in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial. HIV Med 2015 0.75
39 INVESTIGATING THE EFFICACY OF CLINICAL TRIAL MONITORING STRATEGIES: Design and Implementation of the Cluster Randomized START Monitoring Substudy. Ther Innov Regul Sci 2015 0.75
Next 100